The Globe and Mail

EVUSHELD™ long-acting antibody combination retains neutralizing activity against Omicron variants including BA.2 in new independent studies

In addition, in vivo (live organism) data generated using mice infected with Omicron BA.1, BA.1.1 and BA.2 demonstrated that EVUSHELD significantly reduced the viral burden and limited inflammation in ...
Nasdaq

EVUSHELD long-acting antibody combination retains neutralizing activity against Omicron variant in independent FDA study

Only antibody authorized in the US for pre-exposure prophylaxis of COVID-19 WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca’s EVUSHELD (tixagevimab co-packaged with cilgavimab), a long-acting antibody ...
Business Wire

EVUSHELD (formerly AZD7442) long-acting antibody combination authorized for emergency use in the US for pre-exposure prophylaxis (prevention) of COVID-19

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's EVUSHELD (tixagevimab co-packaged with cilgavimab), a long-acting antibody (LAAB) combination, has received emergency use authorization (EUA) in the US ...
Stockhouse

EVUSHELD(TM) significantly protected against symptomatic COVID-19 for at least six months in PROVENT Phase III trial in high-risk populations

Detailed results from the PROVENT Phase III pre-exposure prophylaxis (prevention) trial showed that AstraZeneca’s EVUSHELD™(tixagevimab and cilgavimab), formerly AZD7442, reduced the ...
Nasdaq

EVUSHELD long-acting antibody combination retains neutralizing activity against Omicron variant in studies from Oxford and Washington Universities

WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca’s EVUSHELD (tixagevimab co-packaged with cilgavimab), a long-acting antibody combination for the prevention of COVID-19, retains neutralization activity ...
Monthly Prescribing Reference

Evusheld Authorized for Pre-exposure Prophylaxis of COVID-19 in Certain Individuals

The EUA was supported by primary data from the phase 3 PROVENT trial. The Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for Evusheld (tixagevimab co-packaged with ...
Healio

Evusheld, aggressive therapy may reduce COVID-19 severity in patients on B-cell depletion

Please provide your email address to receive an email when new articles are posted on . Pre-exposure prophylaxis with Evusheld, combined with aggressive outpatient treatment, may reduce COVID-19 ...
Pharmabiz

AstraZeneca's LAAB combination, Evusheld receives emergency use authorisation in US for pre-exposure prophylaxis of Covid-19

AstraZeneca's Evusheld (tixagevimab co-packaged with cilgavimab), a long-acting antibody (LAAB) combination, has received emergency use authorisation (EUA) in the US for the pre-exposure prophylaxis ...
Zawya

Evusheld significantly protected against symptomatic COVID-19 for at least six months

Pre-exposure prophylaxis (prevention) trial reduced risk of symptomatic COVID-19, with no severe disease or COVID-19-related deaths in Evusheld group data published in the New England Journal of ...
Business Wire

EVUSHELD long-acting antibody combination retains neutralizing activity against Omicron variant in independent FDA study

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s EVUSHELD (tixagevimab co-packaged with cilgavimab), a long-acting antibody combination for the prevention of COVID-19, retained neutralizing activity ...
Benzinga.com

EVUSHELD™ long-acting antibody combination retains neutralizing activity against Omicron variants including BA.2 in new independent studies

First in vivo data from Washington University show EVUSHELD reduces viral burden of all tested Omicron subvariants in the lungs In addition, in vivo (live organism) data generated using mice infected ...
PharmiWeb

Evusheld significantly protected against symptomatic COVID-19 for at least six months in PROVENT Phase III trial in high-risk populations

Detailed results from the PROVENT Phase III pre-exposure prophylaxis (prevention) trial showed that AstraZeneca’s Evusheld (tixagevimab and cilgavimab), formerly AZD7442, reduced the risk of ...